Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Dec 27:12:1756287220980192.
doi: 10.1177/1756287220980192. eCollection 2020 Jan-Dec.

Enfortumab Vedotin in urothelial cancer

Marie Alt  1 , Carlos Stecca  1 , Swanee Tobin  1 , Di Maria Jiang  1 , Srikala S Sridhar  2
Affiliations
Review

Enfortumab Vedotin in urothelial cancer

Marie Alt et al. Ther Adv Urol. .

Abstract

The treatment landscape for metastatic urothelial cancer (mUC) beyond first-line platinum-based chemotherapy has changed significantly over the last 5 years with the recent approvals of the immune checkpoint inhibitors (ICIs), fibroblast growth factor receptor (FGFR) inhibitors and most recently Enfortumab Vedotin (EV). EV is a novel antibody-drug conjugate (ADC), that delivers monomethyl auristatin E (MMAE), a microtubule-disrupting agent, inside cells harboring the cell surface nectin-4 receptor. In mUC, EV has shown encouraging response rates and received accelerated approval from the Food and Drug Administration (FDA) in December 2019 in the post-platinum and ICI setting. EV is generally well tolerated, with the main toxicities being neuropathy, skin rash, alopecia and fatigue. Notably EV can also be administered to patients with renal dysfunction, which is commonly a concern in this patient population. EV is now being tested in combination strategies and in earlier disease settings in urothelial cancers. In this review, we will discuss its mechanism of action, clinical trials leading to FDA approval as well as ongoing trials and future directions.

Keywords: Antibody-drug conjugates; Enfortumab Vedotin; Metastatic Urothelial Carcinoma.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: Dr. Sridhar has received research funding from Bayer, Janssen, and honoraria from Roche, Merck, Pfizer, Astra Zeneca, BMS, Janssen, Bayer, Astellas, Sanofi Aventis, Immunomedex.

Figures

Figure 1.
Figure 1.
Enfortumab Vedotin Structure.
See this image and copyright information in PMC

References

    1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68: 394–424. - PubMed
    1. von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000; 18: 3068–3077. - PubMed
    1. Bellmunt J, de Wit R, Vaughn DJ, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med 2017; 376: 1015–1026. - PMC - PubMed
    1. Sridhar SS, Blais N, Tran B, et al. Cctg BL12: randomized phase II trial comparing nab-paclitaxel (Nab-P) to paclitaxel (P) in patients (pts) with advanced urothelial cancer progressing on or after a platinum containing regimen (NCT02033993). J Clin Oncol 2018; 36: 4505.
    1. Bellmunt J, Theodore C, Demkov T, et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol 2009; 27: 4454–4461. - PubMed

LinkOut - more resources